Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings

References

• AsamuraHGoyaTKoshiishiYA Japanese lung cancer registry study: prognosis of 13,010 resected lung cancersJ Thorac Oncol200831465218166840
   PubMed Web of Science ®Google Scholar
• SawabataNMiyaokaEAsamuraHJapanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decadeJ Thorac Oncol2011671229123521610521
   PubMed Web of Science ®Google Scholar
• TravisWDBrambillaENoguchiMInternational Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinomaJ Thorac Oncol20116224428521252716
   PubMed Web of Science ®Google Scholar
• ZhangYSunYXiangJZhangYHuHChenHA clinicopathologic prediction model for postoperative recurrence in stage Ia non-small cell lung cancerJ Thorac Cardiovasc Surg201414841193119924667022
   PubMed Web of Science ®Google Scholar
• CasaliCRossiGMarchioniAA single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practiceJ Thorac Oncol20105683083620521350
   PubMed Web of Science ®Google Scholar
• GoldsteinNSThomasMMucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodiesAm J Clin Pathol2001116331932511554157
   PubMed Web of Science ®Google Scholar
• WislezMAntoineMBaudrinLNon-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinibLung Cancer201068218519119581016
   PubMed Web of Science ®Google Scholar
• WatanabeHSaitoHYokoseTRelation between thin-section computed tomography and clinical findings of mucinous adenocarcinomaAnn Thorac Surg201599397598125624054
   PubMedGoogle Scholar
• LeeHYLeeKSHanJMucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisonsLung Cancer200965217017519111932
   PubMed Web of Science ®Google Scholar
• EdelmanMJWatsonDWangXEicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy–Cancer and Leukemia Group B Trial 30203J Clin Oncol200826684885518281656
   PubMedGoogle Scholar
• SimsirAWeiXJYeeHMoreiraACangiarellaJDifferential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimensAm J Clin Pathol2004121335035715023039
   PubMedGoogle Scholar
• HeYWZhaoMLYangXYZengJDengQHHeJXPrognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancerCancer Chemother Pharmacol201575486186725732635
   PubMedGoogle Scholar
• SèvePLaiRDingKClass III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10Clin Cancer Res200713399499917289895
   PubMed Web of Science ®Google Scholar
• HidalgoMPlazaCMusteanuMSPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT TrialClin Cancer Res201521214811481826169969
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• NagaiYMiyazawaHHuqunGenetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clampCancer Res200565167276728216105816
   PubMed Web of Science ®Google Scholar
• HungJJJengWJChouTYPrognostic value of the new international association for the study of lung cancer/American thoracic society/European respiratory society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinomaAnn Surg201325861079108623532112
   PubMed Web of Science ®Google Scholar
• RussellPABarnettSAWalkiewiczMCorrelation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patientsJ Thorac Oncol20138446146823486266
   PubMed Web of Science ®Google Scholar
• WarthAMuleyTMeisterMThe novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European respiratory society classification system of lung adenocarcinoma is a stage-independent predictor of survivalJ Clin Oncol201230131438144622393100
   PubMed Web of Science ®Google Scholar
• TsutaKKawagoMInoueEThe utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterationsLung Cancer201381337137623891509
   PubMed Web of Science ®Google Scholar
• YoshizawaAMotoiNRielyGJImpact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I casesMod Pathol201124565366421252858
   PubMed Web of Science ®Google Scholar
• CadranelJQuoixEBaudrinLIFCT-0401 Trial Group IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtypeJ Thorac Oncol2009491126113519574932
   PubMedGoogle Scholar
• TangERSchreinerAMPuaBBAdvances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS)J Thorac Dis20146Suppl 5S489S50125349701
   PubMedGoogle Scholar
• ConsortiFLorenzottiAMidiriGDi PaolaMPrognostic significance of mucinous carcinoma of colon and rectum: a prospective case-control studyJ Surg Oncol2000732707410694641
   PubMed Web of Science ®Google Scholar
• EnciuMAşchieMDeacuMPoinăreanuIMorphological characteristics of a mucinous adenocarcinoma of the prostate: differential diagnosis considerationsRom J Morphol Embryol201354119119423529329
   PubMed Web of Science ®Google Scholar
• KunisakiCAkiyamaHNomuraMClinicopathologic characteristics and surgical outcomes of mucinous gastric carcinomaAnn Surg Oncol200613683684216604474
   PubMed Web of Science ®Google Scholar
• BeattyPLNarayananSGariépyJRanganathanSFinnOJVaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancerCancer Prev Res (Phila)20103443844620332301
   PubMed Web of Science ®Google Scholar
• LordRVBrabenderJGandaraDLow ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancerClin Cancer Res2002872286229112114432
   PubMed Web of Science ®Google Scholar
• OlaussenKADunantAFouretPDNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapyN Engl J Med20063551098399116957145
   PubMed Web of Science ®Google Scholar
• SevePMackeyJIsaacSClass III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxelMol Cancer Ther20054122001200716373715
   PubMed Web of Science ®Google Scholar
• ReimanTLaiRVeillardASCross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trialsAnn Oncol2012231869321471564
   PubMedGoogle Scholar
• BeplerGWilliamsCSchellMJRandomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancerJ Clin Oncol201331192404241223690416
   PubMed Web of Science ®Google Scholar
• NicolsonMCFennellDAFerryDThymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trialJ Thorac Oncol20138793093923722170
   PubMed Web of Science ®Google Scholar
• ShimizuTNakanishiYNakagawaYAssociation between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancerAnticancer Res201232104589459623060591
   PubMed Web of Science ®Google Scholar
• BradshawADDiverse biological functions of the SPARC family of proteinsInt J Biochem Cell Biol201244348048822249026
   PubMed Web of Science ®Google Scholar
• NagarajuGPDontulaREl-RayesBFLakkaSSMolecular mechanisms underlying the divergent roles of SPARC in human carcinogenesisCarcinogenesis201435596797324675529
   PubMed Web of Science ®Google Scholar
• HanWCaoFChenMBPrognostic value of SPARC in patients with pancreatic cancer: a systematic review and meta-analysisPLoS One201611e014580326731428
   PubMedGoogle Scholar
• SatoNFukushimaNMaeharaNSPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactionsOncogene2003225021503012902985
   PubMed Web of Science ®Google Scholar
• DesaiNTrieuVKnauerDSPARC may be a predictive biomarker of response to nab-paclitaxelEur J Cancer200972388
   Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar